



RN 18238-08-9 CAPLUS

CN 2(1H)-Quinoxalinone, 5,6,7,8-tetrachloro- (9CI) (CA INDEX NAME)



RN 18392-45-5 CAPLUS

CN Quinoxaline, 5,6,7,8-tetrachloro-2,3-bis(dichloromethyl)- (8CI) (CA INDEX NAME)



GI For diagram(s), see printed CA Issue.

AB 4,5,6,7-Tetrachlorobenzotriazole and its 1-hydroxy deriv. were reduced with Zn and HCl to give 3,4,5,6-tetrachloro-o-phenylenediamine (I, R = Cl) in good yield. The corresponding diamines (I, R = Me or F) were obtained similarly from 4,5,7-trichloro-6-methyl-(or fluoro)benzotriazole. Alternative syntheses of the tetrachloro- and methyltrichlorophenylenediamines are described. Benzimidazoles, quinoxalines, and other heterocycles derived from the diamines, esp. from tetrachloro-o-phenylenediamine, are reported. 26 references.

L4 ANSWER 243 OF 250 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1967:496531 CAPLUS

DN 67:96531

TI Quinoxalines as analytical reagents. I. Derivatives containing the copper(I)-specific grouping

AU Stephen, William I.; Uden, Peter C.

CS Univ. Birmingham, Birmingham, UK

SO Analytica Chimica Acta (1967), 39(3), 357-68

CODEN: ACACAM; ISSN: 0003-2670

DT Journal

LA English


IT 17401-72-8P 17401-73-9P

RL: PREP (Preparation)

(prepn. of)


RN 17401-72-8 CAPLUS

CN Quinoxaline, 6,7-dichloro-2,3-di-2-pyridinyl- (9CI) (CA INDEX NAME)



RN 17401-73-9 CAPLUS

CN Quinoxaline, 6,7-dichloro-2,3-bis(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



AB The prepn., phys. properties, and Cu(I) chelating properties are described of 2,3-bis(2-pyridyl)-quinoxaline (I), 12 derivs. of I prepd. from 2,2'-pyridil[1,2-dioxo-1,2-di(2-pyridyl)ethane]; 2,3-bis[2-(6-methylpyridyl)]quinoxaline (II), and 12 derivs. of II prepd. from 6,6'-dimethyl-2,2'-pyridil[1,2-dioxo-1,2-bis-(6-methylpyridyl)ethane] and aromatic or heterocyclic diamines. I and II and the 24 derivs. contain the Cu(I)-specific cuproine grouping: X-C:N-C-C-N:C-X. The max. absorption and molar absorptivities, ϵ , in EtOH soln., are given of I, II, the 24 analogs of I and II; and of the Cu(I) chelates of the same compds., after extg. into amyl alc. at pH 4.7. To det. 1-100 ppm. Cu²⁺ with II, add to a 1-ml. aliquot of the Cu²⁺ soln. 10 ml. of pH 4.7 0.1M NaOAc-0.1M HOAc buffer, 1 ml. of 1% aq. NH₂OH.HCl or freshly prepd. 1% ascorbic acid soln., and 4 ml. of 0.1% II (in EtOH). Mix well, and ext. twice with 4-ml. vols. of isoamyl alc., and collect the org. exts. in a flask. Dil. to 10 ml. with isoamyl alc., and measure the absorbance of the soln. at 525 m. μ . vs. isoamylalc. Beer's law holds for 0-100 ppm. of Cu²⁺ in the final ext. Prep. the absorbanceconc. calibration graph in the same way with known amts. of Cu²⁺. The limit of detection is 1:5 times. 107, approx. the same as that for cuproine. The reaction of Cu²⁺ with I gives an orange aq. soln. (max. 445 m. μ .) at high Cu²⁺/I ratios; when the I is increased, the broad max. becomes approx. 500 m. μ .. Only Ti³⁺ at pH <2 (max. 608 m. μ . with II) gave a color reaction with the quinoxaline compds. In the given conditions, Ti³⁺ and Fe²⁺ in cation/Cu²⁺ ratios of 100 do not interfere.

L4 ANSWER 244 OF 250 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1965:416869 CAPLUS


DN 63:16869

OREF 63:2973d-g

TI The dimethyl sulfoxide oxidation of 2,3-bis(bromomethyl)quinoxaline

AU Moriconi, Emil J.; Fritsch, Albert J.


[3]




CM 2

CRN 42151-56-4
 CMF Cl1 H17 N O

Absolute stereochemistry. Rotation (+).



GI



I

AB The title compds. [I; R = (un)substituted 5-membered heteroaryl contg. 3 or 4 N atoms which is linked to the quinoxalinedione ring by a ring C or N atom, or a 6-membered heteroaryl contg. 1-3 N atoms which is linked to the quinoxalinedione ring by a ring C atom; R1, R2 = H, F, Cl, Cl-4 alkyl, etc.], useful as NMDA receptor antagonists for treating acute neurodegenerative and chronic neurol. disorders such as stroke, transient ischemic attack, peri-operative ischemia or traumatic head injury, were prepd. and formulated. Thus, treatment of 6,7-dichloro-2,3-dimethoxy-5-(4-pyridyl)quinoxaline with 2N HCl in 1,4-dioxane afforded 17% I [R = 4-pyridyl; R1 = R2 = H]. Compd. I [R = 1-methyl-1H-tetrazol-5-yl; R1 = R2 = Cl] showed IC50 of 3 nM against binding at the glycine site of the NMDA receptor.

L12 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2003 ACS on STN

Patel

<11/14/2003>

AN 1992:592207 CAPLUS

DN 117:192207

Fluorine-19 NMR studies on the mechanism of riboflavin synthase

Synthesis of 6-(trifluoromethyl)-7-oxo-8-(D-ribityl)lumazine and

6-(trifluoromethyl)-7-methyl-8-(D-ribityl)lumazine

Cushman, Mark; Patel, Hemantkumar H.; Scheuring, Johannes; Bacher,

Adelbert

Sch. Pharm. Pharm. Sci., Purdue Univ., West Lafayette, IN, 47907, USA

Journal of Organic Chemistry (1992), 57(21), 5630-43

CODEN: JOCEAH; ISSN: 0022-3263

DT Journal

LA English


IT 143309-87-9P

RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of)

RN 143309-87-9 CAPLUS

CN Quinoxaline, 6,7-dichloro-2-methyl-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title oxo-(D-ribityl)lumazine I was synthesized by reaction of Me trifluoropyruvate with 5-amino-6-(D-ribitylamino)pyrimidine-2,4(1H,3H)-dione hydrochloride and utilized as a ^{19}F NMR probe of the light riboflavin synthase of *Bacillus subtilis*. I was found to be an inhibitor of riboflavin synthase with an inhibition const. $K_I = 55 \mu\text{M}$. The enzyme-bound ligand gave rise to several broad ^{19}F NMR signals which were shifted to low field. The bound ligand I could be displaced from the enzyme by the enzyme product, riboflavin (II), and the product analog, 5-nitroso-6-(ribitylamino)-2,4(1H,3H)-pyrimidinedione. Title methyl-(D-ribityl)lumazine III was synthesized by reaction of 5-amino-6-(D-ribitylamino)pyrimidine-2,4(1H,3H)-dione hydrochloride with 1,1,1-trifluorobutane-2,3-dione. Three mols. of III can be bound relatively tightly per mol of riboflavin synthase, i.e., one ligand mol. per protein subunit. A scheme for the catalytic cycle of riboflavin synthase is proposed.

L12 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1974:536183 CAPLUS

DN 81:136183

TI Antibacterial 3-cyano-2-hydroxyquinoxaline N,N'-dioxides

IN Seng, Florin; Ley, Kurt

PA Bayer A.-G.


SO Ger. Offen., 15 pp.

Patel


<11/14/2003>

Condensation of II (R = H) with CO(CH₂CO₂Et)₂ gave III.

L3 ANSWER 876 OF 1398 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1980:76440 CAPLUS
 DN 92:76440
 TI Reaction of 6-chloroquinoxaline with potassium amide in liquid ammonia
 AU Czuba, Wladyslaw; Poradowska, Henryka
 CS Inst. Org. Chem. Technol., Tech. Univ., Krakow, Pol.
 SO Zeszyty Naukowe Uniwersytetu Jagiellonskiego, Prace Chemiczne (1979), 24,
 7-12
 CODEN: ZUJCAQ; ISSN: 0373-0166
 DT Journal
 LA English
 IT 2427-70-5P 52312-40-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of, by amination of chloroquinoxaline)
 RN 2427-70-5 CAPLUS
 CN 2-Quinoxalinamine, 7-chloro- (9CI) (CA INDEX NAME)



RN 52312-40-0 CAPLUS
 CN 2,3-Quinoxalinediamine, 6-chloro- (9CI) (CA INDEX NAME)




AB Amination of 3.292 g 6-chloroquinoxaline with 4-fold excess KNH₂-NH₃ gave traces of 6-aminoquinoxaline together with 2.141 g 3-amino-6-chloroquinoxaline and 0.413 g 2,3-diamino-6-chloroquinoxaline.


L3 ANSWER 877 OF 1398 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1980:33916 CAPLUS
 DN 92:33916
 TI Toxicity tests and residue determinations, in chickens, of a coccidiostat composed of sulfaquinoxaline and diaveridine
 AU Gennaro Soffietti, Maria; Tappero, P.
 CS Fac. Med. Chir., Univ. Torino, Turin, Italy
 SO Annali della Facolta di Medicina Veterinaria di Torino (1978), 25, 230-5
 CODEN: AMVTAA; ISSN: 0496-4748
 DT Journal
 LA Italian
 IT 65566-74-7
 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
 (residues and toxicity of, in chicken)
 RN 65566-74-7 CAPLUS
 CN Benzenesulfonamide, 4-amino-N-2-quinoxaliny-, mixt. with

the column chromatog. by boiling water bath. The ext. was cleaned by alumina column chromatog. and followed by ion-paired subjected to HPLC on a .mu.Bondapak C18 column, followed by ion-paired recovery rate of 97.4% chromatog. and detn. at OD254. The method had a recovery rate of 97.4% pelletized and powder form and a relative std. deviation of 2.8% for both pelletized and powder form feed mixes.

L3. ANSWER 712 OF 1398 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1985:437081 CAPLUS
 DN 103:37081
 TI Reactivity of cyanodithioformate towards primary amines
 AU De Diego, Carmen; Gomez, Encarnacion; Avendano, Carmen
 CS Fac. Farm., Univ. Complutense, Madrid, 28040, Spain
 SO Heterocycles (1985), 23(3), 649-51
 CODEN: HTCYAM; ISSN: 0385-5414
 DT Journal
 LA English
 OS CASREACT 103:37081
 IT 34972-19-5 97122-10-6 97183-62-5
 RL: RCT (Reactant); RACT (Reactant or reagent))
 RN 34972-19-5 CAPLUS
 CN 2(1H)-Quinoxalinethione, 3-amino- (9CI) (CA INDEX NAME)




RN 97122-10-6 CAPLUS
 CN 2(1H)-Quinoxalinethione, 3-amino-6(or 7)-methyl- (9CI) (CA INDEX NAME)



D1-Me


* RN 97183-62-5 CAPLUS
 CN 2-Quinoxalinamine, 3-(ethylthio)- (9CI) (CA INDEX NAME)



GI

Patel

<11/9/2003>



AB Dithiooxamides RNHCSCSNHR (R = PhCH₂, PhCH₂CH₂, Bu, cyclohexyl) were obtained by the reaction of NCCS₂Me (I) with RNH₂. o-Phenylenediamines underwent cycloaddn.-cyclocondensation with I to yield quinoxalines II (R₁ = H, Me). I and PhNH₂ gave PhNHCSNHPH, while NCC(:NNHCONHPh)SMe was obtained from I and H₂NNHCONHPh.

L3 ANSWER 713 OF 1398 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1985:431967 CAPLUS

DN 103:31967

TI Relationship between the hydrophobic substitution constants obtained from pyridine derivatives and those from benzene derivatives

AU Kim, Ki Hwan; Martin, Yvonne C.

CS Abbott Lab., North Chicago, IL, USA

SO QSAR Des. Bioact. Compd. (1984), 61-7. Editor(s): Kuchar, M. Publisher: Prous, Barcelona, Spain.
CODEN: 53SIAU

DT Conference

LA English


IT 5424-05-5 6479-24-9

RL: BIQL (Biological study)

(hydrophobic substituent consts. prediction for, QSAR studies in relation to)


RN 5424-05-5 CAPLUS

CN 2-Quinoxalinamine (9CI) (CA INDEX NAME)



RN 6479-24-9 CAPLUS

CN Acetamide, N-2-quinoxaliny- (8CI, 9CI) (CA INDEX NAME)



GI

IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
 MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
 SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

GB 1999-8175 A 19990409


IT 153504-81-5, Aceal021

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(treatment of neurol. disorders with nitric oxide synthase inhibitors and excitatory amino receptor modulators)

RN 153504-81-5 CAPLUS

CN 2,3-Quinoxalinedione, 6,7-dichloro-1,4-dihydro-5-nitro- (9CI) (CA INDEX NAME)



AB The present invention relates to a method of treating a neurol. disorder comprising administering to a patient an effective amt. of a nitric oxide synthase inhibitor in combination with an effective amt. of an excitatory amino receptor modulator. Combination of 2.5 mg/kg Mk-801, i.p., and 25 mg/kg ARL17477, i.p., had a synergistic degree of neuroprotection (78%) in cerebral ischemia induced in gerbils.

L4 ANSWER 36 OF 250 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2000:493530 CAPLUS

DN 133:89542

TI Preparation of quinoxalines as non-peptide GLP-1 agonists

IN Teng, Min; Truesdale, Larry Kenneth; Bhumralkar, Dilip; Kiel, Dan; Johnson, Michael D.; Thomas, Christine; Jorgensen, Anker Steen; Madsen, Peter; Olesen, Preben Houlberg; Knudsen, Liselotte Bjerre; Petterson, Ingrid Vivika; Cornelis De Jong, Johannes; Behrens, Carsten; Kodra, Janos Tibor; Lau, Jesper

PA Novo Nordisk A/S, Den.; Agouron Pharmaceuticals, Inc.

SO PCT Int. Appl., 194 pp.

CODEN: PIXXD2


DT Patent

LA English


FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000042026	A1	20000720	WO 2000-DK14	20000114
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,				


SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 DK 1999-41 A 19990115
 EP 1147094 A1 20011024 EP 2000-900499 20000114
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO
 DK 1999-41 A 19990115
 WO 2000-DK14 W 20000114
 JP 2002534512 T2 20021015 JP 2000-593594 20000114
 DK 1999-41 A 19990115
 WO 2000-DK14 W 20000114
 OS MARPAT 133:89542
 IT 108230-00-8P 149366-38-1P 212771-50-1P
 281208-75-1P 281208-76-2P 281208-77-3P
 281208-78-4P 281208-79-5P 281208-80-8P
 281208-81-9P 281208-82-0P 281208-83-1P
 281208-84-2P 281208-85-3P 281208-87-5P
 281208-88-6P 281208-89-7P 281208-90-0P
 281208-93-3P 281209-07-2P 281209-08-3P
 281209-09-4P 281209-12-9P 281209-13-0P
 281209-16-3P 281209-17-4P 281209-18-5P
 281209-19-6P 281209-21-0P 281209-22-1P
 281209-24-3P 281209-25-4P 281209-27-6P
 281209-28-7P 281209-29-8P 281209-30-1P
 281209-31-2P 281209-32-3P 281209-49-2P
 281209-50-5P 281209-57-2P 281209-66-3P
 281209-67-4P 281209-69-6P 281209-79-8P
 281209-96-9P 281210-00-2P 281210-10-4P
 281210-29-5P 281210-30-8P 281211-09-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of quinoxalines as non-peptide GLP-1 agonists)
 RN 108230-00-8 CAPLUS
 CN 2-Quinoxalinecarboxylic acid, 3,6,7-trichloro-, ethyl ester (9CI) (CA
 INDEX NAME)




RN 149366-38-1 CAPLUS
 CN Quinoxaline, 2,6,7-trichloro-3-(2-phenylethenyl)- (9CI) (CA INDEX NAME)




RN 212771-50-1 CAPLUS
CN Quinoxaline, 2,6,7-trichloro-3-methyl- (9CI) (CA INDEX NAME)




RN 281208-75-1 CAPLUS
CN Quinoxaline, 6,7-dichloro-2-(1-methylethyl)-3-[(5-methyl-1,3,4-thiadiazol-2-yl)thio]- (9CI) (CA INDEX NAME)




RN 281208-76-2 CAPLUS
CN Quinoxaline, 6,7-dichloro-2-[(5-methyl-1,3,4-thiadiazol-2-yl)thio]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 281208-77-3 CAPLUS
CN 1,3,5-Triazin-2-amine, 4-[[6,7-dichloro-3-(1-methylethyl)-2-quinoxaliny]thio]- (9CI) (CA INDEX NAME)







RN 281208-78-4 CAPLUS
 CN Quinoxaline, 2,2'-thiobis[6,7-dichloro-3-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 281208-79-5 CAPLUS
 CN Quinoxaline, 6,7-dichloro-2-[(5-methyl-1,3,4-thiadiazol-2-yl)thio]- (9CI) (CA INDEX NAME)



RN 281208-80-8 CAPLUS
 CN Quinoxaline, 6,7-dichloro-2-(1-methylethyl)-3-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 281208-81-9 CAPLUS
 CN Quinoxaline, 6,7-dichloro-2-(1-methylethyl)-3-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 281208-82-0 CAPLUS

CN Quinoxaline, 6,7-dichloro-2-(1-methylethyl)-3-[[5-(methylthio)-1,3,4-thiadiazol-2-yl]thio]- (9CI) (CA INDEX NAME)




RN 281208-83-1 CAPLUS

CN Quinoxaline, 6,7-dichloro-2-[[5-[(cyclopropylmethyl)thio]-1,3,4-thiadiazol-2-yl]thio]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 281208-84-2 CAPLUS

CN Quinoxaline, 6,7-dichloro-2-(1-methylethyl)-3-[[4-methyl-5-(trifluoromethyl)-4H-1,2,4-triazol-3-yl]thio]- (9CI) (CA INDEX NAME)




RN 281208-85-3 CAPLUS


CN 1H-1,2,4-Triazol-3-amine, 5-[[[6,7-dichloro-3-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)-2-quinoxaliny]methyl]thio]- (9CI) (CA INDEX NAME)




RN 281208-87-5 CAPLUS
CN Quinoxaline, 2,6,7-trichloro-3-[2-(4-fluorophenyl)ethenyl]- (9CI) (CA INDEX NAME)




RN 281208-88-6 CAPLUS
CN Quinoxaline, 2-chloro-6,7-difluoro-3-methyl- (9CI) (CA INDEX NAME)



RN 281208-89-7 CAPLUS
CN Quinoxaline, 2-chloro-6,7-difluoro-3-(2-phenylethenyl)- (9CI) (CA INDEX NAME)




RN 281208-90-0 CAPLUS
CN Quinoxaline, 2,6,7-trichloro-3-[[1-methyl-1H-tetrazol-5-yl]thio]methyl]- (9CI) (CA INDEX NAME)




RN 281208-93-3 CAPLUS

CN 1H-1,2,4-Triazol-3-amine, 5-[[3,6,7-trichloro-2-quinoxaliny]methyl]thio]-
(9CI) (CA INDEX NAME)




RN 281209-07-2 CAPLUS

CN Quinoxaline, 2,6,7-trichloro-3-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 281209-08-3 CAPLUS

CN Quinoxaline, 2,6,7-trichloro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 281209-09-4 CAPLUS

CN Quinoxaline, 2,6,7-trichloro-3-(2-furanyl)- (9CI) (CA INDEX NAME)




RN 281209-12-9 CAPLUS


CN Quinoxaline, 2,6,7-trichloro-3-(chloromethyl)- (9CI) (CA INDEX NAME)




RN 281209-13-0 CAPLUS
 CN Quinoxaline, 2,6,7-trichloro-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 281209-16-3 CAPLUS
 CN 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 6-[[3,6,7-trichloro-2-quinoxaliny]methyl]thio]- (9CI) (CA INDEX NAME)



RN 281209-17-4 CAPLUS
 CN Quinoxaline, 2,6,7-trichloro-3-[[1-phenyl-1H-tetrazol-5-yl]thio]methyl]- (9CI) (CA INDEX NAME)




RN 281209-18-5 CAPLUS
 CN 1,3,4-Thiadiazol-2-amine, 5-[[6,7-dichloro-3-(1-methylethyl)-2-quinoxaliny]thio]- (9CI) (CA INDEX NAME)




RN 281209-19-6 CAPLUS

CN Cyclopropaneacetamide, N-[5-[[6,7-dichloro-3-(1-methylethyl)-2-quinoxaliny]thio]-1,3,4-thiadiazol-2-yl]- (9CI) (CA INDEX NAME)




RN 281209-21-0 CAPLUS

CN 1H-1,2,4-Triazol-3-amine, 5-[[6,7-dichloro-3-(1-methylethyl)-2-quinoxaliny]thio]- (9CI) (CA INDEX NAME)




RN 281209-22-1 CAPLUS

CN Quinoxaline, 6,7-dichloro-2-[[3-chloro-5-(trifluoromethyl)-2-pyridiny]thio]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 281209-24-3 CAPLUS


CN 2-Quinoxalinamine, 6,7-dichloro-3-(2-furanyl)-N-2-propynyl- (9CI) (CA INDEX NAME)




RN 281209-25-4 CAPLUS
 CN Ethanol, 2-[[6,7-dichloro-3-(2-furanyl)-2-quinoxaliny]amino]- (9CI) (CA INDEX NAME)




RN 281209-27-6 CAPLUS
 CN Quinoxaline, 2-bromo-6,7-dichloro-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 281209-28-7 CAPLUS
 CN Quinoxaline, 2-bromo-6,7-dichloro-3-(2-phenylethenyl)- (9CI) (CA INDEX NAME)




RN 281209-29-8 CAPLUS
 CN Quinoxaline, 2-bromo-6,7-dichloro-3-[(methylsulfonyl)methyl]- (9CI) (CA INDEX NAME)




RN 281209-30-1 CAPLUS

CN Quinoxaline, 6,7-dichloro-2-(1-methylethyl)-3-[(4-methyl-2-thiazolyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 281209-31-2 CAPLUS

CN Quinoxaline, 6,7-dichloro-2-(1-methylethyl)-3-[(4-methyl-2-thiazolyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 281209-32-3 CAPLUS

CN Quinoxaline, 6,7-dichloro-2-(1-methylethyl)-3-[(1-methyl-1H-imidazol-5-yl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 281209-49-2 CAPLUS

CN Quinoxaline, 6,7-dichloro-2-[(4-methyl-2-thiazolyl)sulfonyl]-3-propyl- (9CI) (CA INDEX NAME)




RN 281209-50-5 CAPLUS

CN Quinoxaline, 6,7-dichloro-2-[(4-methyl-2-thiazolyl)sulfinyl]-3-propyl- (9CI) (CA INDEX NAME)




RN 281209-57-2 CAPLUS

CN Quinoxaline, 6,7-dichloro-2-[(1-methyl-1H-tetrazol-5-yl)sulfinyl]-3-propyl-
(9CI) (CA INDEX NAME)




RN 281209-66-3 CAPLUS

CN Quinoxaline, 6,7-dichloro-2-[(1-methyl-1H-tetrazol-5-yl)sulfonyl]-3-propyl-
(9CI) (CA INDEX NAME)




RN 281209-67-4 CAPLUS

CN Quinoxaline, 6,7-dichloro-2-[(1-phenyl-1H-tetrazol-5-yl)sulfinyl]-3-propyl-
(9CI) (CA INDEX NAME)




RN 281209-69-6 CAPLUS

CN Quinoxaline, 6,7-dichloro-2-[(1-phenyl-1H-tetrazol-5-yl)sulfonyl]-3-propyl-
(9CI) (CA INDEX NAME)




RN 281209-79-8 CAPLUS

CN Quinoxaline, 6,7-dichloro-2-[(1-methyl-1H-imidazol-2-yl)sulfonyl]-3-propyl-
(9CI) (CA INDEX NAME)




RN 281209-96-9 CAPLUS

CN Quinoxaline, 5,6,7,8-tetrachloro-2-(1-methylethyl)-3-[(1-methyl-1H-imidazol-2-yl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 281210-00-2 CAPLUS


CN 2-Quinoxalinamine, 6,7-dichloro-N-(1-methylethyl)-3-[(1-methyl-1H-imidazol-2-yl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 281210-10-4 CAPLUS

CN 2-Quinoxalinamine, 6,7-dichloro-N-(1,1-dimethylethyl)-3-[(1-methyl-1H-


imidazol-2-yl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 281210-29-5 CAPLUS

CN Quinoxaline, 2-(2-benzoxazolylsulfonyl)-6,7-dichloro-3-(trifluoromethyl)-
(9CI) (CA INDEX NAME)

RN 281210-30-8 CAPLUS

CN Quinoxaline, 6,7-dichloro-2-(2-thiazolylsulfonyl)-3-(trifluoromethyl)-
(9CI) (CA INDEX NAME)

RN 281211-09-4 CAPLUS

CN 2-Quinoxalinamine, 3,6,7-trichloro-N-(1,1-dimethylethyl)- (9CI) (CA INDEX
NAME)

IT 25983-13-5 75293-93-5 153504-81-5


209743-15-7 281210-92-2 281210-98-8

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of quinoxalines as non-peptide GLP-1 agonists)


RN 25983-13-5 CAPLUS

CN 2,3-Quinoxalinedione, 6,7-dichloro-1,4-dihydro- (7CI, 9CI) (CA INDEX NAME)




RN 75293-93-5 CAPLUS

CN 2-Quinoxalinecarboxylic acid, 6,7-dichloro-3,4-dihydro-3-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 153504-81-5 CAPLUS

CN 2,3-Quinoxalinedione, 6,7-dichloro-1,4-dihydro-5-nitro- (9CI) (CA INDEX NAME)




RN 209743-15-7 CAPLUS

CN 2-Quinoxalinamine, 3,6,7-trichloro- (9CI) (CA INDEX NAME)




RN 281210-92-2 CAPLUS


CN 2-Quinoxalinamine, 3,6,7-trichloro-N-(1-methylethyl)-8-nitro- (9CI) (CA INDEX NAME)




RN 281210-98-8 CAPLUS
 CN 2,3-Quinoxalinediamine, 6,7-dichloro-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




IT 281210-52-4P 281210-54-6P 281210-56-8P
 281210-58-0P 281210-60-4P 281210-62-6P
 281210-64-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of quinoxalines as non-peptide GLP-1 agonists)
 RN 281210-52-4 CAPLUS
 CN Quinoxaline, 2,6,7-trichloro-3-propyl- (9CI) (CA INDEX NAME)




RN 281210-54-6 CAPLUS
 CN Quinoxaline, 2,6,7-trichloro-3-ethyl- (9CI) (CA INDEX NAME)




RN 281210-56-8 CAPLUS
 CN Quinoxaline, 2,6,7-trichloro-3-(2-phenylethyl)- (9CI) (CA INDEX NAME)







RN 281210-58-0 CAPLUS
CN 2(1H)-Quinoxalinethione, 6,7-dichloro-3-(trifluoromethyl)- (9CI) (CA INDEX, NAME)




RN 281210-60-4 CAPLUS
CN 2(1H)-Quinoxalinethione, 6,7-dichloro-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 281210-62-6 CAPLUS
CN 2(1H)-Quinoxalinethione, 6,7-dichloro-3-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)



RN 281210-64-8 CAPLUS
CN 2(1H)-Quinoxalinethione, 6,7-dichloro-3-[(1,1-dimethylethyl)amino]- (9CI) (CA INDEX NAME)



GI

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 51 OF 250 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1999:549272 CAPLUS
 DN 131:170359
 TI Preparation of substituted quinoxaline derivatives as interleukin-8
 receptor antagonists
 IN Carson, Kenneth G.; Connor, David Thomas; Li, Jie Jack; Low, Joseph Edwin;
 Luly, Jay R.; Miller, Steven Robert; Roth, Bruce David; Trivedi, Bharat
 Kalidas
 PA Warner-Lambert Company, USA
 SO PCT Int. Appl., 200 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9942463	A1	19990826	WO 1999-US2581	19990205
	W:			AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	
	RW:			GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	
	AU 9926603	A1	19990906	US 1998-75551P P	19980223
				AU 1999-26603	19990205
				US 1998-75551P P	19980223
				WO 1999-US2581 W	19990205
	ZA 9901413	A	19990830	ZA 1999-1413	19990222
				US 1998-75551P P	19980223
	US 6548499	B1	20030415	US 2000-622423	20001020
				US 1998-75551P P	19980223
				WO 1999-US2581 W	19990205

PATENT FAMILY INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9942461	A1	19990826	WO 1998-US26707	19981215
	W:			AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	
	RW:			GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	
	AU 9919182	A1	19990906	US 1998-75551P P	19980223
				AU 1999-19182	19981215
				US 1998-75551P P	19980223
				WO 1998-US26707W	19981215
	ZA 9901413	A	19990830	ZA 1999-1413	19990222
				US 1998-75551P P	19980223



OS MARPAT 131:170359
 IT 239094-68-9P 239094-69-0P 239094-70-3P
 239094-71-4P 239094-72-5P 239094-73-6P
 239094-74-7P 239094-75-8P 239094-78-1P

239094-79-2P 239094-80-5P 239094-81-6P
 239094-82-7P 239094-83-8P 239094-84-9P
 239094-87-2P 239094-91-8P 239094-92-9P
 239094-95-2P 239094-96-3P 239094-97-4P
 239094-98-5P 239094-99-6P 239095-00-2P
 239095-01-3P 239095-02-4P 239095-03-5P
 239095-05-7P 239095-06-8P 239095-07-9P
 239095-08-0P 239095-09-1P 239095-11-5P
 239095-12-6P 239095-15-9P 239095-16-0P
 239095-18-2P 239095-19-3P 239095-20-6P
 239095-22-8P 239095-23-9P 239095-24-0P
 239095-25-1P 239095-26-2P 239095-27-3P
 239095-28-4P 239095-29-5P 239095-30-8P
 239095-31-9P 239095-33-1P 239095-34-2P
 239095-36-4P 239095-37-5P 239095-39-7P
 239095-40-0P 239095-41-1P 239095-42-2P
 239095-43-3P 239095-45-5P 239095-46-6P
 239095-47-7P 239095-48-8P 239095-51-3P
 239095-52-4P 239095-65-9P 239095-72-8P
 239095-73-9P 239095-74-0P 239095-75-1P
 239095-76-2P 239095-77-3P 239095-78-4P
 239095-79-5P 239095-80-8P 239095-81-9P
 239095-82-0P 239095-83-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of substituted quinoxaline derivs. as interleukin receptor antagonists)

RN 239094-68-9 CAPLUS


CN 1,4-Cyclohexanediamine, N'-[6,7-dichloro-3-(2-pyridinyl)-2-quinoxaliny]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 239094-69-0 CAPLUS


CN 1,4-Cyclohexanediamine, N-[6,7-dichloro-3-(2-pyridinyl)-2-quinoxaliny]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 239094-70-3 CAPLUS

CN Quinoxaline, 2-[1,4'-bipiperidin]-1'-yl-6,7-dichloro-3-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 239094-71-4 CAPLUS

CN 2-Quinoxalinamine, 6,7-dichloro-N-[4-[(diethylamino)methyl]phenyl]-3-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 239094-72-5 CAPLUS


CN 1,3-Propanediamine, N'-[6,7-dichloro-3-(2-furanyl)-2-quinoxalinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 239094-73-6 CAPLUS
 CN 1,3-Propanediamine, N'-[6,7-dichloro-3-(2-thienyl)-2-quinoxaliny]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 239094-74-7 CAPLUS
 CN 1,4-Butanedi-amine, N'-[6,7-dichloro-3-(2-furanyl)-2-quinoxaliny]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 239094-75-8 CAPLUS
 CN 1,4-Butanedi-amine, N'-[6,7-difluoro-3-(2-thienyl)-2-quinoxaliny]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 239094-78-1 CAPLUS
 CN Butanimidamide, 4-[[6,7-dichloro-3-(5-methyl-2-thienyl)-2-quinoxaliny]amino]- (9CI) (CA INDEX NAME)



RN 239094-79-2 CAPLUS
 CN Butanimidamide, 4-[[6,7-dichloro-3-(5-methyl-2-thienyl)-2-quinoxaliny]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 239094-78-1
 CMF C17 H17 Cl2 N5 S




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 239094-80-5 CAPLUS
 CN Pyrrolidine, 1-[4-[[6,7-dichloro-3-(2-thienyl)-2-quinoxaliny]amino]-1-iminobutyl]- (9CI) (CA INDEX NAME)



RN 239094-81-6 CAPLUS
 CN Pyrrolidine, 1-[4-[[6,7-dichloro-3-(2-thienyl)-2-quinoxaliny]amino]-1-iminobutyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 239094-80-5
CMF C20 H21 Cl2 N5 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 239094-82-7 CAPLUS
CN 1,4-Butanediamine, N'-[6,7-dichloro-3-(2-thienyl)-2-quinoxalinyloxy]-N,N-diethyl-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl


RN 239094-83-8 CAPLUS
CN 1H-Indole, 2-[6,7-dichloro-3-[[4-(diethylamino)butyl]amino]-2-quinoxalinyloxy]-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 239094-84-9 CAPLUS
 CN 1,4-Butanediamine, N'-[6,7-dichloro-3-(1H-indol-2-yl)-2-quinoxaliny]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 239094-87-2 CAPLUS
 CN 1,4-Butanediamine, N'-(3-benzo[b]thien-2-yl-6,7-dichloro-2-quinoxaliny)-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 239094-91-8 CAPLUS
 CN 1,4-Butanediamine, N'-[6,7-dichloro-3-(5-methyl-2-thienyl)-2-quinoxaliny]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 239094-92-9 CAPLUS
 CN 1,4-Butanediamine, N'-[6,7-dichloro-3-(5,6-dihydro-1,4-dioxin-2-yl)-2-quinoxaliny]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 239094-95-2 CAPLUS

CN 1,4-Butanediamine, N'-[6,7-dichloro-3-(1-ethoxyethenyl)-2-quinoxalinyloxy]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 239094-96-3 CAPLUS

CN 1,3-Propanediamine, N'-[6,7-dichloro-3-(2-thiazolyl)-2-quinoxalinyloxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 239094-97-4 CAPLUS

CN 1,4-Butanediamine, N'-[3-[2,2'-bithiophen]-5-yl-6,7-dichloro-2-quinoxalinyloxy]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 239094-98-5 CAPLUS

CN 1,4-Butanediamine, N'-[6,7-dichloro-3-(5-chloro-2-thienyl)-2-quinoxalinyloxy]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 239094-99-6 CAPLUS

CN 1,4-Butanediamine, N'-[6,7-dichloro-3-(5-methoxy-2-thienyl)-2-quinoxalinylyl]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 239095-00-2 CAPLUS

CN 1,4-Butanediamine, N'-[6,7-dichloro-3-(5-propyl-2-thienyl)-2-quinoxalinylyl]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 239095-01-3 CAPLUS

CN 1,4-Butanediamine, N'-[3-(2-benzofuranyl)-6,7-dichloro-2-quinoxalinylyl]-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 239095-02-4 CAPLUS


CN 1,4-Butanediamine, N'-[6,7-dichloro-3-(5-chloro-3-methylbenzo[b]thien-2-yl)-2-quinoxalinylyl]-N,N-diethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 239095-03-5 CAPLUS


CN 1,4-Butanediamine, N'-[6,7-dichloro-3-(4-dibenzothiienyl)-2-quinoxaliny]-N,N-diethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 239095-05-7 CAPLUS


CN 2-Quinoxalinamine, 6,7-dichloro-3-(5-phenyl-2-oxazolyl)-N-[4-(1-pyrrolidinyl)butyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 239095-06-8 CAPLUS


CN 2-Quinoxalinamine, 6,7-dichloro-N-[4-(1-pyrrolidinyl)butyl]-3-[5-(2-thienyl)-2-oxazolyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 239095-07-9 CAPLUS


CN 2-Quinoxalinamine, 6,7-dichloro-3-[5-(2-pyridinyl)-2-oxazolyl]-N-[4-(1-pyrrolidinyl)butyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 239095-08-0 CAPLUS

CN 2-Quinoxalinamine, 6,7-dichloro-3-(5-phenyl-2-thienyl)-N-[4-(1-pyrrolidinyl)butyl]-, dihydrochloride (9CI) (CA INDEX NAME)





● 2 HCl

RN 239095-09-1 CAPLUS
CN 1,4-Butanediamine, N'-[6,7-dichloro-3-(5-phenyl-2-thienyl)-2-quinoxaliny]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)





● 2 HCl


RN 239095-11-5 CAPLUS
CN 1,4-Cyclohexanediamine, N'-[6,7-dichloro-3-(3-pyridinyl)-2-quinoxaliny]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)




RN 239095-12-6 CAPLUS
CN 1,4-Cyclohexanediamine, N'-[6,7-dichloro-3-(4-pyridinyl)-2-quinoxaliny]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)




RN 239095-15-9 CAPLUS
CN 1,2-Ethanediamine, N'-[6,7-dichloro-3-(2-pyridinyl)-2-quinoxaliny]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 239095-16-0 CAPLUS
CN 1,3-Propanediamine, N'-[6,7-dichloro-3-(2-pyridinyl)-2-quinoxaliny]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 239095-18-2 CAPLUS
CN 1,4-Butanediamine, N'-[6,7-dichloro-3-(2-pyridinyl)-2-quinoxaliny]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 239095-19-3 CAPLUS
CN 1,5-Pentanediamine, N'-[6,7-dichloro-3-(2-pyridinyl)-2-quinoxaliny]-N,N-dimethyl- (9CI) (CA INDEX NAME)





RN 239095-20-6 CAPLUS

CN 1,6-Hexanediamine, N'-[6,7-dichloro-3-(2-pyridinyl)-2-quinoxaliny]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 239095-22-8 CAPLUS

CN 2-Quinoxalinamine, 6,7-dichloro-N-[3-(4-morpholinyl)propyl]-3-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 239095-23-9 CAPLUS

CN 2-Quinoxalinamine, 6,7-dichloro-N-(3-methoxypropyl)-3-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 239095-24-0 CAPLUS

CN 1,3-Propanediamine, N-(3-aminopropyl)-N'-[6,7-dichloro-3-(2-pyridinyl)-2-quinoxaliny]-N-methyl- (9CI) (CA INDEX NAME)





RN 239095-25-1 CAPLUS

CN Ethanol, 2,2'-[[3-[[6,7-dichloro-3-(2-pyridinyl)-2-quinoxaliny]amino]propyl]imino]bis- (9CI) (CA INDEX NAME)




RN 239095-26-2 CAPLUS

CN 2-Quinoxalinamine, 6,7-dichloro-N-[4-[4-(2-chlorophenyl)-1-piperazinyl]butyl]-3-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 239095-27-3 CAPLUS

CN 2-Quinoxalinamine, 6,7-dichloro-N-[1-phenyl-4-(1-piperidinyl)butyl]-3-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 239095-28-4 CAPLUS


CN 2-Quinoxalinamine, 6,7-dichloro-3-(1-ethyl-5-phenyl-1H-imidazol-2-yl)-N-[4-(1-pyrrolidinyl)butyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 239095-29-5 CAPLUS



CN 2-Quinoxalinamine, 6,7-dichloro-3-(1-phenyl-1H-imidazol-2-yl)-N-[4-(1-pyrrolidinyl)butyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 239095-30-8 CAPLUS

CN 2-Quinoxalinamine, 6,7-dichloro-3-[1-ethyl-2-(5-methyl-2-thienyl)-1H-imidazol-5-yl]-N-[4-(1-pyrrolidinyl)butyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 239095-31-9 CAPLUS
CN 2-Quinoxalinamine, 6,7-dichloro-3-(1-phenyl-1H-pyrazol-5-yl)-N-[4-(1-pyrrolidinyl)butyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 239095-33-1 CAPLUS
CN 1,4-Butanediamine, N'-[6,7-dichloro-3-(2-furanyl)-2-quinoxalinyll]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 239095-34-2 CAPLUS
CN 1,4-Butanediamine, N'-[6,7-dichloro-3-(2-thienyl)-2-quinoxalinyll]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 239095-36-4 CAPLUS

CN 1,4-Butanediamine, N'-[6,7-dichloro-3-(5-chloro-3-methylbenzo[b]thien-2-yl)-2-quinoxaliny]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 239095-37-5 CAPLUS

CN 1,4-Butanediamine, N'-[6,7-dichloro-3-(4-dibenzothiienyl)-2-quinoxaliny]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 239095-39-7 CAPLUS

CN 2-Quinoxalinamine, 6,7-dichloro-3-(5-phenyl-2-oxazolyl)-N-[4-(1-pyrrolidinyl)butyl]- (9CI) (CA INDEX NAME)




RN 239095-40-0 CAPLUS

CN 2-Quinoxalinamine, 6,7-dichloro-N-[4-(1-pyrrolidinyl)butyl]-3-[5-(2-thienyl)-2-oxazolyl]- (9CI) (CA INDEX NAME)




RN 239095-41-1 CAPLUS

CN 2-Quinoxalinamine, 6,7-dichloro-3-[5-(2-pyridinyl)-2-oxazolyl]-N-[4-(1-pyrrolidinyl)butyl]- (9CI) (CA INDEX NAME)




RN 239095-42-2 CAPLUS

CN 2-Quinoxalinamine, 6,7-dichloro-3-(5-phenyl-2-thienyl)-N-[4-(1-pyrrolidinyl)butyl]- (9CI) (CA INDEX NAME)




RN 239095-43-3 CAPLUS

CN 1,4-Butanediamine, N'-[6,7-dichloro-3-(5-phenyl-2-thienyl)-2-quinoxalinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 239095-45-5 CAPLUS

CN 2-Quinoxalinamine, 6,7-dichloro-3-(1-ethyl-5-phenyl-1H-imidazol-2-yl)-N-[4-(1-pyrrolidinyl)butyl]- (9CI) (CA INDEX NAME)





RN 239095-46-6 CAPLUS

CN 2-Quinoxalinamine, 6,7-dichloro-3-(1-phenyl-1H-imidazol-2-yl)-N-[4-(1-pyrrolidinyl)butyl]- (9CI) (CA INDEX NAME)




RN 239095-47-7 CAPLUS

CN 2-Quinoxalinamine, 6,7-dichloro-3-[1-ethyl-2-(5-methyl-2-thienyl)-1H-imidazol-5-yl]-N-[4-(1-pyrrolidinyl)butyl]- (9CI) (CA INDEX NAME)




RN 239095-48-8 CAPLUS

CN 2-Quinoxalinamine, 6,7-dichloro-3-(1-phenyl-1H-pyrazol-5-yl)-N-[4-(1-pyrrolidinyl)butyl]- (9CI) (CA INDEX NAME)





RN 239095-51-3 CAPLUS

CN 1,2-Ethanediamine, N'-[6,7-dichloro-3-(2-pyridinyl)-2-quinoxaliny]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 239095-52-4 CAPLUS


CN 2-Quinoxalinamine, 6,7-dichloro-3-(2-pyridinyl)-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 239095-65-9 CAPLUS



CN Quinoxaline, 6,7-dichloro-2-methyl-3-(1-piperazinyl)- (9CI) (CA INDEX NAME)





RN 239095-72-8 CAPLUS

CN 1,4-Cyclohexanediamine, N'-[6,7-dichloro-3-(2-pyridinyl)-2-quinoxalinyll]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 239095-73-9 CAPLUS

CN 1,4-Cyclohexanediamine, N-[6,7-dichloro-3-(2-pyridinyl)-2-quinoxalinyll]-, dihydrochloride, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



2 HCl

RN 239095-74-0 CAPLUS


CN Quinoxaline, 2-[1,4'-bipiperidin]-1'-yl-6,7-dichloro-3-(2-pyridinyl)-, hydrochloride (3:4) (9CI) (CA INDEX NAME)



● 4/3 HCl

RN 239095-75-1 CAPLUS


CN 1,3-Propanediamine, N'-[6,7-dichloro-3-(2-furanyl)-2-quinoxalinyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 239095-76-2 CAPLUS


CN 1,3-Propanediamine, N'-[6,7-dichloro-3-(2-thienyl)-2-quinoxalinyl]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 239095-77-3 CAPLUS

CN 1,4-Butanediamine, N'-[6,7-dichloro-3-(1H-indol-2-yl)-2-quinoxalinyl]-N,N-diethyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 239095-78-4 CAPLUS
CN 1,3-Propanediamine, N'-(6,7-dichloro-3-(2-thiazolyl)-2-quinoxaliny)-N,N-dimethyl-, hydrochloride (2:3) (9CI) (CA INDEX NAME)




● 3/2 HCl

RN 239095-79-5 CAPLUS
CN 1,4-Butanedi-amine, N'-(3-[2,2'-bithiophen]-5-yl-6,7-dichloro-2-quinoxaliny)-N,N-diethyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 239095-80-8 CAPLUS
CN 1,4-Butanedi-amine, N'-(6,7-dichloro-3-(5-chloro-2-thienyl)-2-quinoxaliny)-N,N-diethyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 239095-81-9 CAPLUS
 CN 1,4-Butanediamine, N'-[6,7-dichloro-3-(5-methoxy-2-thienyl)-2-quinoxaliny]-N,N-diethyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 239095-82-0 CAPLUS
 CN 1,4-Butanediamine, N'-[6,7-dichloro-3-(5-propyl-2-thienyl)-2-quinoxaliny]-N,N-diethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 239095-83-1 CAPLUS
 CN 1,4-Butanediamine, N'-[3-(2-benzofuranyl)-6,7-dichloro-2-quinoxaliny]-N,N-diethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


IT 239095-99-9

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of substituted quinoxaline derivs. as interleukin receptor antagonists)

RN 239095-99-9 CAPLUS

CN Quinoxaline, 2,6,7-trichloro-3-(2-pyridinyl)- (9CI) (CA INDEX NAME)



IT 25983-13-5P 232604-10-3P 232604-24-9P

232604-25-0P 232604-28-3P 239095-85-3P

239095-87-5P 239095-88-6P 239095-89-7P

239095-90-0P 239095-91-1P 239095-92-2P


239095-97-7P 239095-98-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of substituted quinoxaline derivs. as interleukin receptor antagonists)


RN 25983-13-5 CAPLUS


CN 2,3-Quinoxalinedione, 6,7-dichloro-1,4-dihydro- (7CI, 9CI) (CA INDEX NAME)



RN 232604-10-3 CAPLUS


CN 2-Quinoxalinamine, 3-bromo-6,7-dichloro- (9CI) (CA INDEX NAME)






RN 232604-24-9 CAPLUS

CN 2-Quinoxalinamine, 6,7-dichloro-3-(2-furanyl)- (9CI) (CA INDEX NAME)




RN 232604-25-0 CAPLUS

CN 2-Quinoxalinamine, 6,7-dichloro-3-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 232604-28-3 CAPLUS

CN 1H-Indole, 2-(3-amino-6,7-dichloro-2-quinoxaliny)-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 239095-85-3 CAPLUS

CN 2-Quinoxalinamine, 6,7-dichloro-3-(2-thienyl)- (9CI) (CA INDEX NAME)




RN 239095-87-5 CAPLUS

CN 1,4-Butanediamine, N'-(3-bromo-6,7-dichloro-2-quinoxaliny)-N,N-diethyl-
(9CI) (CA INDEX NAME)




RN 239095-88-6 CAPLUS

CN 1,4-Butanediamine, N'-(3-bromo-6,7-dichloro-2-quinoxaliny)-N,N-dimethyl-
(9CI) (CA INDEX NAME)




RN 239095-89-7 CAPLUS

CN 2(1H)-Quinoxalinone, 6,7-dichloro-3-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 239095-90-0 CAPLUS

CN Quinoxaline, 2,6,7-trichloro-3-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 239095-91-1 CAPLUS

CN 2(1H)-Quinoxalinone, 6,7-dichloro-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 239095-92-2 CAPLUS

CN Quinoxaline, 2,6,7-trichloro-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 239095-97-7 CAPLUS

CN Carbamic acid, [5-[[6,7-dichloro-3-(2-pyridinyl)-2-quinoxaliny]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 239095-98-8 CAPLUS

CN 1,5-Pentanediamine, N-[6,7-dichloro-3-(3-pyridinyl)-2-quinoxaliny]- (9CI) (CA INDEX NAME)



GI